You've got me thinking - although the trial is mostly funded by the NIH, the actual sponsor is the Icahn School of Medicine at Mount Sinai. So I will correct that statement and say the DSMB was appointment by the school rather than Mesoblast. Given the relationship with Silviu, previous trials and the school however - I would say that Meso would still have a major part in dealing with the DSMB.
Overwhelming efficacy - the stats required, page-275
-
- There are more pages in this discussion • 302 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.38 |
Change
-0.080(5.50%) |
Mkt cap ! $1.569B | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.43 | $1.37 | $5.321M | 3.829M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 12214 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.38 | 37660 | 5 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |